Findings

What do systematic reviews say?

16 questions · 17 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 13 · 76.5%GRADE not reported 0 · 0%Very low 2 · 11.8%Low 0 · 0%Moderate 1 · 5.9%High 1 · 5.9%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Tricylic antidepressant vs placebo · Change in quality of life
  Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Very low
Direct match · question page
- Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (SSRI/SNRI) therapy with placebo · Quality of life (EQ‐5D‐5L) ‐ 12 weeks
  Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 447 participants
  High
Direct match · question page
- Antidepressant vs placebo · Quality of life
  Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Related · question page
- New‐generation antidepressants vs placebo · Functional disability and quality of life (post‐treatment score on self report scales) Different self report scales (SF‐36, SDS)
  Pharmacological interventions for somatoform disorders in adults 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 163 participants
  Very low
Related · question page
- Augmentation of current antidepressant (various) with quetiapine (150 mg/d to 300 mg/d) vs augmentation of current antidepressant (various) with placebo · Quality of life (% max score of Q‐LES‐Q‐SF) ‐ Any dose Scale from: 0 to 100 (better)
  Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 884 participants
  Moderate

Antidepressants vs antidepressants

Quality of life · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressants vs antipsychotics

Quality of life · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressants vs placebo

Quality of life · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tricyclic antidepressants vs placebo

Functional disability and quality of life (post‐treatment score on self report and clinician‐rated scales) · somatoform disorders in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for somatoform disorders in adults 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

New‐generation antidepressants vs placebo

Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · somatoform disorders in adults

1 finding from 1 review

Pharmacological interventions for somatoform disorders in adults 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 163 participants
Very low

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) vs augmentation of current antidepressant (various) with placebo

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressant plus antipsychotic vs placebo

Quality of life · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressant plus antipsychotic vs placebo/no adjunctive treatment + antipsychotics

Quality of life · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressant plus antipsychotic vs placebo plus antidepressant

Quality of life · adults with psychotic depression

The review found no eligible studies for this question.

2 findings from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Quality of life (EQ‐5D‐5L) ‐ 12 weeks · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 447 participants
High

Tricylic antidepressant vs placebo

Change in quality of life · chronic obstructive pulmonary disease (COPD) with depression

1 finding from 1 review

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Augmentation of current antidepressant (various) with quetiapine (150 mg/d to 300 mg/d) vs augmentation of current antidepressant (various) with placebo

Quality of life (% max score of Q‐LES‐Q‐SF) ‐ Any dose Scale from: 0 to 100 (better) · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 884 participants
Moderate